Astellas and Poseida Therapeutics Enter Into Research Collab

- Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR® programs targeting solid tumors -
TOKYO and SAN DIEGO, May 1, 2024 /PRNewswire/ -- Astellas...

Related Keywords

Tokyo , Japan , Xyphos Biosciences , Astellas Pharma , Kristin Yarema , Naoki Okamura , Adam Pearson , Linkedin , Astellas Company , Poseida Therapeutics Inc , Nasdaq , Exchange Commission , Pearson , Xyphos Biosciences Inc , Areas Of Interest Astellas Pharma Inc , Astellas Pharma Inc , Poseida Therapeutics , Chimeric Antigen Receptor , Chief Strategy Officer , Primary Focus , Focus Area Approach , South San Francisco , Site Specific Gene Editing System , Booster Molecule , Looking Statements , Private Securities Litigation Reform Act , Markets ,